BioNTech SE (LON:0A3M)

London flag London · Delayed Price · Currency is GBP · Price in USD
107.00
-10.45 (-8.90%)
At close: Apr 25, 2025
Market Cap 18.62B
Revenue (ttm) 2.28B
Net Income (ttm) -550.18M
Shares Out n/a
EPS (ttm) -2.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,609
Average Volume 3,001
Open 120.00
Previous Close 117.45
Day's Range 101.61 - 118.73
52-Week Range 59.62 - 104.32
Beta 1.08
RSI 54.14
Earnings Date May 5, 2025

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in ph... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Employees 6,772
Stock Exchange London Stock Exchange
Ticker Symbol 0A3M
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

There is no news available yet.